Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.
about
Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer RiskAn Immunohistochemical Algorithm for Ovarian Carcinoma Typing.Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C statusOvarian cancer epidemiology in the era of collaborative team science.Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary diseaseArid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.Clinical and Emergent Biomarkers and Their Relationship to the Prognosis of Ovarian Cancer.Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records.A targeted genetic association study of epithelial ovarian cancer susceptibility.Trefoil factor 3 expression in epithelial ovarian cancer exerts a minor effect on clinicopathological parameters.The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteinsComprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes.Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.Ovarian cancer: diagnostic, biological and prognostic aspects.Mutational heterogeneity in non-serous ovarian cancers.Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse.Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes.The diagnostic role of PTEN and ARID1A in serous effusions.Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.Targeted mutation analysis of endometrial clear cell carcinoma.
P2860
Q26799669-7BC78740-A5B9-4280-A108-3907A1CBBA38Q27313766-8A160879-8C0C-47F3-9DAA-6D5DCC323C55Q28307436-B394E9B6-C0CA-49DE-A1A6-FACAA43D9D8BQ30252987-01ABF43C-953B-434F-866E-2FB195379775Q34687073-E86E43D7-A347-42DD-B65C-276242A2ACF6Q36157106-810535DA-9D40-429B-816A-623316C14BFCQ36248459-CB948EDA-DDC1-4904-A978-FADC69F5EFADQ36469778-1E022C95-3F1A-4115-BEB9-17BC0A615A90Q36609391-34D99C86-9A9E-455C-910F-810A3C33C3D3Q36866311-5354F990-01A6-4F72-94DD-C1B3D57F7F36Q36946511-23735D78-80B9-4A1E-8958-6FA3CAB9A6CCQ37287502-34A51D73-5621-4EDE-8C4B-B901C053A059Q37396607-BFDA961C-4CBB-4D80-8F04-1E7000797A91Q37485636-143C6E3F-BB1A-47D1-B271-F1E091463C74Q37729055-5583E560-0602-40F6-B904-341F46EAFCE8Q38205584-AC9182C7-9285-4C66-82F3-BB6CCD9640D2Q38261795-04E597F5-24B1-4D93-B984-7183677F4585Q38602953-9B138CFA-EF79-4E33-9712-3790A6BB2498Q38693040-91D4F004-F348-4DA2-99C9-69A2EAF0ACCBQ38787667-F112D7E1-A788-461F-AA04-EB4A8C83AAE7Q40277712-70ADD978-E8A7-4B9E-AB06-3C461413BC1DQ40397279-DEEB7D8E-44B4-47AE-995F-3C4C8B235452Q42671513-B49F765E-CA93-4165-97E7-93E48F25A2CEQ43924266-B6CA9DB0-B266-4B4E-BDC2-EA43ADA48DA1Q45933729-CE18C5FB-77ED-4B89-B691-55B448B56DDCQ47369086-673F6602-4D05-41AE-BDAE-E9CBA64DA060Q48110433-D449A69C-95CF-46CF-B35E-4D5E6B4F1707Q52675313-45693245-7F95-4308-895D-C6B7AB680919Q52723773-F148AF18-571D-4CA1-B52D-317047A76D05Q54188782-AAAEF81F-B021-45D4-982B-AF0BCB388F4E
P2860
Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biomarker-based ovarian carcin ...... or tissue analysis consortium.
@en
Biomarker-based ovarian carcin ...... or tissue analysis consortium.
@nl
type
label
Biomarker-based ovarian carcin ...... or tissue analysis consortium.
@en
Biomarker-based ovarian carcin ...... or tissue analysis consortium.
@nl
prefLabel
Biomarker-based ovarian carcin ...... or tissue analysis consortium.
@en
Biomarker-based ovarian carcin ...... or tissue analysis consortium.
@nl
P2093
P2860
P50
P1476
Biomarker-based ovarian carcin ...... or tissue analysis consortium.
@en
P2093
Brooke L Fridley
C Blake Gilks
Christine Chow
Clareann Bunker
Daniel W Visscher
David G Huntsman
Elizabeth Benjamin
Ellen L Goode
Eva L Wozniak
Gary L Keeney
P2860
P304
P356
10.1158/1055-9965.EPI-13-0391
P50
P577
2013-07-23T00:00:00Z